Dennis Dlugos
Neurology with Special Qualifications in Child Neurology · Philadelphia, PANPI 1669486551
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $78,781 of the $88,302 with a category attached, or 89.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 19.7%. Among neurology with special qualifications in child neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $1090.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$17K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Jazz Pharmaceuticals Inc.$10K
- Neurocrine Biosciences, Inc.$8K
- Immedica Pharma US, Inc.$6K
- Pfizer$5K
- plus $29K from 15 others
Across 34 payments — averaging $7414.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$156K
- Aquestive Therapeutics, Inc.$71K
- Immedica Pharma US, Inc.$15K
- Neurelis, Inc.$5K
- Biogen$3K
- UCB, Inc.$2K
What the payments were for
- Consulting fees$78,78189%
- Speaking & faculty fees$6,7388%
- Travel & lodging$1,2491%
- Food & beverage$1,5352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 15 | $17,379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $13,888 |
| Jazz Pharmaceuticals Inc. | 10 | $9,638 |
| Neurocrine Biosciences, Inc. | 11 | $7,762 |
| Immedica Pharma US, Inc. | 1 | $5,650 |
| Pfizer | 1 | $5,444 |
| Biocodex, Inc. | 5 | $5,366 |
| Biogen | 6 | $4,918 |
| GW Research Limited | 3 | $4,250 |
| UCB SA | 1 | $3,042 |
| UCB GmbH | 1 | $2,106 |
| UCB Biosciences Inc. | 2 | $1,800 |
| Supernus Pharmaceuticals, Inc. | 2 | $1,500 |
| Sage Therapeutics, LLC | 2 | $1,275 |
| Aquestive Therapeutics, Inc. | 1 | $1,020 |
| Acadia Pharmaceuticals Inc | 2 | $1,013 |
| Biomarin Pharmaceutical Inc. | 5 | $887 |
| DIXI Medical USA Corp | 1 | $833 |
| Zogenix Inc. | 1 | $400 |
| Lundbeck LLC | 1 | $100 |
| Eisai Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,302 in reported general payments places this provider in the 95th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.
See all neurology with special qualifications in child neurology providers in Pennsylvania →
Other neurology with special qualifications in child neurology in Philadelphia
- John BrandsemaPhiladelphia$526K
- Susan MatesanzPhiladelphia$138K
- Elizabeth KichulaPhiladelphia$90K
- Alexandra KornbluhPhiladelphia$88K
- Nicholas AbendPhiladelphia$56K
- Sabrina YumPhiladelphia$33K
- Eric MarshPhiladelphia$28K
- Christina SzperkaPhiladelphia$18K
- David LynchPhiladelphia$16K
- Marissa DigiovinePhiladelphia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.